Publications by authors named "Feng-Ya Shih"
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity.
J Allergy Clin Immunol Pract
January 2025
Article Synopsis
- - Osimertinib is an effective lung cancer drug, but it can cause severe allergic reactions, especially in Asian patients, which can complicate treatment.
- - A study of 17 patients showed that the genetic marker HLA-B*51:02 was found in a high percentage of those experiencing severe allergic reactions (SJS/TEN), indicating a strong genetic predisposition.
- - The presence of HLA-B*51:02 also correlated with higher levels of a specific protein related to these reactions, suggesting that individuals with this genetic marker may be at risk for severe side effects when taking osimertinib.
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
J Eur Acad Dermatol Venereol
February 2023
Purpose: Cutaneous toxicities are common adverse effects following epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy. Zinc deficiency causes diverse diseases, including skin toxicities. Therefore, this study aimed to investigate the role of zinc deficiency in patients with EGFR-TKI-induced skin toxicities.
View Article and Find Full Text PDFBackground: High rates of posttreatment discomfort, infection, recurrence, and increased time to return to work have been noted after nail plate avulsion resulting from epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)-induced paronychia, which may even interrupt the course of treatment for EGFR-TKI therapy. Thus, we conducted this study to determine how effectively a topical β-blocker, betaxolol, prevents EGFR-TKI-induced paronychia.
Methods: This case-control cohort study included a total of 131 non-small-cell lung cancer patients.